Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 288 entries
Sorted by: Best Match Show Resources per page
Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.

The Journal of urology

Kinnaird A, Yerram NK, O'Connor L, Brisbane W, Sharma V, Chuang R, Jayadevan R, Ahdoot M, Daneshvar M, Priester A, Delfin M, Tran E, Barsa DE, Sisk A, Reiter RE, Felker E, Raman S, Kwan L, Choyke PL, Merino MJ, Wood BJ, Turkbey B, Pinto PA, Marks LS.
PMID: 34854746
J Urol. 2021 Dec 02;101097JU0000000000002343. doi: 10.1097/JU.0000000000002343. Epub 2021 Dec 02.

PURPOSE: The underlying premise of prostate cancer active surveillance (AS) is that cancers likely to metastasize will be recognized and eliminated before cancer-related disease can ensue. Our study was designed to determine the prostate cancer upgrading rate when biopsy...

Cite
Kinnaird A, Yerram NK, O'Connor L, et al. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer. J Urol. 2021;101097JU0000000000002343doi: 10.1097/JU.0000000000002343.
Kinnaird, A., Yerram, N. K., O'Connor, L., Brisbane, W., Sharma, V., Chuang, R., Jayadevan, R., Ahdoot, M., Daneshvar, M., Priester, A., Delfin, M., Tran, E., Barsa, D. E., Sisk, A., Reiter, R. E., Felker, E., Raman, S., Kwan, L., Choyke, P. L., Merino, M. J., Wood, B. J., Turkbey, B., Pinto, P. A., & Marks, L. S. (2021). Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer. The Journal of urology, 101097JU0000000000002343. https://doi.org/10.1097/JU.0000000000002343
Kinnaird, Adam, et al. "Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer." The Journal of urology vol. (2021): 101097JU0000000000002343. doi: https://doi.org/10.1097/JU.0000000000002343
Kinnaird A, Yerram NK, O'Connor L, Brisbane W, Sharma V, Chuang R, Jayadevan R, Ahdoot M, Daneshvar M, Priester A, Delfin M, Tran E, Barsa DE, Sisk A, Reiter RE, Felker E, Raman S, Kwan L, Choyke PL, Merino MJ, Wood BJ, Turkbey B, Pinto PA, Marks LS. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer. J Urol. 2021 Dec 02;101097JU0000000000002343. doi: 10.1097/JU.0000000000002343. Epub 2021 Dec 02. PMID: 34854746.
Copy Download .nbib Format: NLM
Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019.

Current opinion in critical care

Di Meglio L, Carriero S, Biondetti P, Wood BJ, Carrafiello G.
PMID: 34864792
Curr Opin Crit Care. 2022 Feb 01;28(1):17-24. doi: 10.1097/MCC.0000000000000906.

PURPOSE OF REVIEW: This review aims to explore the different imaging modalities, such as chest radiography (CXR), computed tomography (CT), ultrasound, PET/CT scan, and MRI to describe the main features for the evaluation of the chest in COVID-19 patients...

Cite
Di Meglio L, Carriero S, Biondetti P, et al. Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019. Curr Opin Crit Care. 2022;28(1):17-24doi: 10.1097/MCC.0000000000000906.
Di Meglio, L., Carriero, S., Biondetti, P., Wood, B. J., & Carrafiello, G. (2022). Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019. Current opinion in critical care, 28(1), 17-24. https://doi.org/10.1097/MCC.0000000000000906
Di Meglio, Letizia, et al. "Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019." Current opinion in critical care vol. 28,1 (2022): 17-24. doi: https://doi.org/10.1097/MCC.0000000000000906
Di Meglio L, Carriero S, Biondetti P, Wood BJ, Carrafiello G. Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019. Curr Opin Crit Care. 2022 Feb 01;28(1):17-24. doi: 10.1097/MCC.0000000000000906. PMID: 34864792; PMCID: PMC8711303.
Copy Download .nbib Format: NLM
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS.
PMID: 34593565
Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30.

BACKGROUND: The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance....

Cite
Monk BJ, Coleman RL, Fujiwara K, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021;31(12):1589-1594doi: 10.1136/ijgc-2021-002933.
Monk, B. J., Coleman, R. L., Fujiwara, K., Wilson, M. K., Oza, A. M., Oaknin, A., O'Malley, D. M., Lorusso, D., Westin, S. N., Safra, T., Herzog, T. J., Marmé, F., N Eskander, R., Lin, K. K., Shih, D., Goble, S., Grechko, N., Hume, S., Maloney, L., McNeish, I. A., & Kristeleit, R. S. (2021). ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 31(12), 1589-1594. https://doi.org/10.1136/ijgc-2021-002933
Monk, Bradley J, et al. "ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 31,12 (2021): 1589-1594. doi: https://doi.org/10.1136/ijgc-2021-002933
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30. PMID: 34593565.
Copy Download .nbib Format: NLM
Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo).

Poultry science

Abdalla EA, Makanjuola BO, van Staaveren N, Wood BJ, Baes CF.
PMID: 34954445
Poult Sci. 2021 Nov 20;101(2):101601. doi: 10.1016/j.psj.2021.101601. Epub 2021 Nov 20.

Pendulous crop (PC) in the turkey occurs when the crop distends from its normal position, thereby preventing the movement of feed and water from the crop down into the digestive system. This condition negatively impacts the turkey industry at...

Cite
Abdalla EA, Makanjuola BO, van Staaveren N, et al. Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poult Sci. 2021;101(2):101601doi: 10.1016/j.psj.2021.101601.
Abdalla, E. A., Makanjuola, B. O., van Staaveren, N., Wood, B. J., & Baes, C. F. (2021). Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poultry science, 101(2), 101601. https://doi.org/10.1016/j.psj.2021.101601
Abdalla, E A, et al. "Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo)." Poultry science vol. 101,2 (2021): 101601. doi: https://doi.org/10.1016/j.psj.2021.101601
Abdalla EA, Makanjuola BO, van Staaveren N, Wood BJ, Baes CF. Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poult Sci. 2021 Nov 20;101(2):101601. doi: 10.1016/j.psj.2021.101601. Epub 2021 Nov 20. PMID: 34954445.
Copy Download .nbib Format: NLM
Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo).

Poultry science

Abdalla EA, Makanjuola BO, van Staaveren N, Wood BJ, Baes CF.
PMID: 34954445
Poult Sci. 2021 Nov 20;101(2):101601. doi: 10.1016/j.psj.2021.101601. Epub 2021 Nov 20.

Pendulous crop (PC) in the turkey occurs when the crop distends from its normal position, thereby preventing the movement of feed and water from the crop down into the digestive system. This condition negatively impacts the turkey industry at...

Cite
Abdalla EA, Makanjuola BO, van Staaveren N, et al. Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poult Sci. 2021;101(2):101601doi: 10.1016/j.psj.2021.101601.
Abdalla, E. A., Makanjuola, B. O., van Staaveren, N., Wood, B. J., & Baes, C. F. (2021). Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poultry science, 101(2), 101601. https://doi.org/10.1016/j.psj.2021.101601
Abdalla, E A, et al. "Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo)." Poultry science vol. 101,2 (2021): 101601. doi: https://doi.org/10.1016/j.psj.2021.101601
Abdalla EA, Makanjuola BO, van Staaveren N, Wood BJ, Baes CF. Accuracy of genomic selection for reducing susceptibility to pendulous crop in turkey (Meleagris gallopavo). Poult Sci. 2021 Nov 20;101(2):101601. doi: 10.1016/j.psj.2021.101601. Epub 2021 Nov 20. PMID: 34954445.
Copy Download .nbib Format: NLM
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Th.

The Journal of thoracic and cardiovascular surgery

Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK, Wolk MJ, Patel MR, Dehmer GJ, Smith PK, Blankenship JC, Bove AA, Bradley SM, Dean LS, Duffy PL, Ferguson TB, Grover FL, Guyton RA, Hlatky MA, Lazar HL, Rigolin VH, Rose GA, Shemin RJ, Tamis-Holland JE, Tommaso CL, Wann LS, Wong JB, Doherty JU, Dehmer GJ, Bailey SR, Bhave NM, Brown AS, Daugherty SL, Desai MY, Duvernoy CS, Gillam LD, Hendel RC, Kramer CM, Lindsay BD, Manning WJ, Patel MR, Sachdeva R, Wann LS, Winchester DE, Wolk MJ, Allen JM.
PMID: 33198024
J Thorac Cardiovasc Surg. 2019 Mar;157(3):e131-e161. doi: 10.1016/j.jtcvs.2018.11.027.

No abstract available.

Cite
Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Th. J Thorac Cardiovasc Surg. 2019;157(3):e131-e161doi: 10.1016/j.jtcvs.2018.11.027.
Patel, M. R., Calhoon, J. H., Dehmer, G. J., Grantham, J. A., Maddox, T. M., Maron, D. J., Smith, P. K., Wolk, M. J., Patel, M. R., Dehmer, G. J., Smith, P. K., Blankenship, J. C., Bove, A. A., Bradley, S. M., Dean, L. S., Duffy, P. L., Ferguson, T. B., Grover, F. L., Guyton, R. A., Hlatky, M. A., Lazar, H. L., Rigolin, V. H., Rose, G. A., Shemin, R. J., Tamis-Holland, J. E., Tommaso, C. L., Wann, L. S., Wong, J. B., Doherty, J. U., Dehmer, G. J., Bailey, S. R., Bhave, N. M., Brown, A. S., Daugherty, S. L., Desai, M. Y., Duvernoy, C. S., Gillam, L. D., Hendel, R. C., Kramer, C. M., Lindsay, B. D., Manning, W. J., Patel, M. R., Sachdeva, R., Wann, L. S., Winchester, D. E., Wolk, M. J., & Allen, J. M. (2019). ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Th. The Journal of thoracic and cardiovascular surgery, 157(3), e131-e161. https://doi.org/10.1016/j.jtcvs.2018.11.027
Patel, Manesh R, et al. "ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Th." The Journal of thoracic and cardiovascular surgery vol. 157,3 (2019): e131-e161. doi: https://doi.org/10.1016/j.jtcvs.2018.11.027
Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK, Wolk MJ, Patel MR, Dehmer GJ, Smith PK, Blankenship JC, Bove AA, Bradley SM, Dean LS, Duffy PL, Ferguson TB, Grover FL, Guyton RA, Hlatky MA, Lazar HL, Rigolin VH, Rose GA, Shemin RJ, Tamis-Holland JE, Tommaso CL, Wann LS, Wong JB, Doherty JU, Dehmer GJ, Bailey SR, Bhave NM, Brown AS, Daugherty SL, Desai MY, Duvernoy CS, Gillam LD, Hendel RC, Kramer CM, Lindsay BD, Manning WJ, Patel MR, Sachdeva R, Wann LS, Winchester DE, Wolk MJ, Allen JM. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Th. J Thorac Cardiovasc Surg. 2019 Mar;157(3):e131-e161. doi: 10.1016/j.jtcvs.2018.11.027. PMID: 33198024.
Copy Download .nbib Format: NLM
Angular needle tracker and stabilizer for image-guided interventions.

Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

Zhao Z, Li R, Xu LJ, Enzmann DR, Wood BJ, Tse ZTH.
PMID: 33207973
Minim Invasive Ther Allied Technol. 2020 Nov 18;1-8. doi: 10.1080/13645706.2020.1832122. Epub 2020 Nov 18.

INTRODUCTION: Minimally invasive image-guided interventions have changed the face of procedural medicine. For these procedures, safety and efficacy depend on precise needle placement. Needle targeting devices help improve the accuracy of needle placement, but their use has not seen...

Cite
Zhao Z, Li R, Xu LJ, et al. Angular needle tracker and stabilizer for image-guided interventions. Minim Invasive Ther Allied Technol. 2020;1-8doi: 10.1080/13645706.2020.1832122.
Zhao, Z., Li, R., Xu, L. J., Enzmann, D. R., Wood, B. J., & Tse, Z. T. H. (2020). Angular needle tracker and stabilizer for image-guided interventions. Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy, 1-8. https://doi.org/10.1080/13645706.2020.1832122
Zhao, Zhuo, et al. "Angular needle tracker and stabilizer for image-guided interventions." Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy vol. (2020): 1-8. doi: https://doi.org/10.1080/13645706.2020.1832122
Zhao Z, Li R, Xu LJ, Enzmann DR, Wood BJ, Tse ZTH. Angular needle tracker and stabilizer for image-guided interventions. Minim Invasive Ther Allied Technol. 2020 Nov 18;1-8. doi: 10.1080/13645706.2020.1832122. Epub 2020 Nov 18. PMID: 33207973.
Copy Download .nbib Format: NLM
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Journal of the National Cancer Institute

Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M.
PMID: 33729494
J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034.

BACKGROUND: There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.METHODS: Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared...

Cite
Wenzel L, Osann K, McKinney C, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021;113(10):1369-1378doi: 10.1093/jnci/djab034.
Wenzel, L., Osann, K., McKinney, C., Cella, D., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., Mok, S. C., Conrads, T. P., Miller, A., Mannel, R. S., Gray, H. J., Hanjani, P., Huh, W. K., Spirtos, N., Leitao, M. M., Glaser, G., Sharma, S. K., Santin, A. D., Sperduto, P., Lele, S. B., Burger, R. A., Monk, B. J., & Birrer, M. (2021). Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 113(10), 1369-1378. https://doi.org/10.1093/jnci/djab034
Wenzel, Lari, et al. "Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival." Journal of the National Cancer Institute vol. 113,10 (2021): 1369-1378. doi: https://doi.org/10.1093/jnci/djab034
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034. PMID: 33729494; PMCID: PMC8486331.
Copy Download .nbib Format: NLM
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.

Gynecologic oncology

Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN.
PMID: 34474927
Gynecol Oncol. 2021 Nov;163(2):254-261. doi: 10.1016/j.ygyno.2021.08.020. Epub 2021 Aug 30.

OBJECTIVE: GAS6 and AXL are expressed in high-grade serous ovarian cancer but not in normal ovarian tissue. AVB-500, a novel high affinity Fc-sAXL fusion protein, binds GAS6 preventing AXL signaling. This Phase 1b study (NCT03639246) evaluated safety, efficacy, and...

Cite
Fuh KC, Bookman MA, Liu JF, et al. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021;163(2):254-261doi: 10.1016/j.ygyno.2021.08.020.
Fuh, K. C., Bookman, M. A., Liu, J. F., Coleman, R. L., Herzog, T. J., Thaker, P. H., Monk, B. J., Anderson, R., McIntyre, G., Rangwala, R., & Moore, K. N. (2021). Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic oncology, 163(2), 254-261. https://doi.org/10.1016/j.ygyno.2021.08.020
Fuh, Katherine C, et al. "Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer." Gynecologic oncology vol. 163,2 (2021): 254-261. doi: https://doi.org/10.1016/j.ygyno.2021.08.020
Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021 Nov;163(2):254-261. doi: 10.1016/j.ygyno.2021.08.020. Epub 2021 Aug 30. PMID: 34474927.
Copy Download .nbib Format: NLM
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Molecular cancer therapeutics

Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ.
PMID: 32847980
Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26.

To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1...

Cite
Tewari KS, Sill MW, Monk BJ, et al. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020;19(11):2363-2370doi: 10.1158/1535-7163.MCT-20-0276.
Tewari, K. S., Sill, M. W., Monk, B. J., Penson, R. T., Moore, D. H., Lankes, H. A., Ramondetta, L. M., Landrum, L. M., Randall, L. M., Oaknin, A., Leitao, M. M., Eisenhauer, E. L., DiSilvestro, P., Van Le, L., Pearl, M. L., Burke, J. J., Salani, R., Richardson, D. L., Michael, H. E., Kindelberger, D. W., & Birrer, M. J. (2020). Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Molecular cancer therapeutics, 19(11), 2363-2370. https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari, Krishnansu S, et al. "Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)." Molecular cancer therapeutics vol. 19,11 (2020): 2363-2370. doi: https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26. PMID: 32847980; PMCID: PMC7907274.
Copy Download .nbib Format: NLM
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.

Future oncology (London, England)

O'Malley DM, Randall LM, Jackson CG, Coleman RL, Hays JL, Moore KN, Naumann RW, Rocconi RP, Slomovitz BM, Tewari KS, Ancukiewicz M, Feliu WO, Monk BJ.
PMID: 34409858
Future Oncol. 2021 Sep;17(26):3433-3443. doi: 10.2217/fon-2021-0529. Epub 2021 Aug 19.

Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new checkpoint inhibitors that have emerged as promising investigational agents for the treatment of cervical cancer, particularly in the setting of previously-treated, recurrent/metastatic disease. Here we describe the rationale and...

Cite
O'Malley DM, Randall LM, Jackson CG, et al. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future Oncol. 2021;17(26):3433-3443doi: 10.2217/fon-2021-0529.
O'Malley, D. M., Randall, L. M., Jackson, C. G., Coleman, R. L., Hays, J. L., Moore, K. N., Naumann, R. W., Rocconi, R. P., Slomovitz, B. M., Tewari, K. S., Ancukiewicz, M., Feliu, W. O., & Monk, B. J. (2021). RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future oncology (London, England), 17(26), 3433-3443. https://doi.org/10.2217/fon-2021-0529
O'Malley, David M, et al. "RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer." Future oncology (London, England) vol. 17,26 (2021): 3433-3443. doi: https://doi.org/10.2217/fon-2021-0529
O'Malley DM, Randall LM, Jackson CG, Coleman RL, Hays JL, Moore KN, Naumann RW, Rocconi RP, Slomovitz BM, Tewari KS, Ancukiewicz M, Feliu WO, Monk BJ. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future Oncol. 2021 Sep;17(26):3433-3443. doi: 10.2217/fon-2021-0529. Epub 2021 Aug 19. PMID: 34409858.
Copy Download .nbib Format: NLM
Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma.

Current oncology (Toronto, Ont.)

Fuller SN, Shafiei A, Venzon DJ, Liewehr DJ, Mauda Havanuk M, Ilanchezhian MG, Edgerly M, Anderson VL, Levy EB, Hoang CD, Jones EC, Reilly KM, Widemann BC, Wood BJ, Bagheri H, Del Rivero J.
PMID: 34898541
Curr Oncol. 2021 Nov 01;28(6):4357-4366. doi: 10.3390/curroncol28060370.

Adrenocortical carcinoma (ACC) is a rare malignancy with an overall unfavorable prognosis. Clinicians treating patients with ACC have noted accelerated growth in metastatic liver lesions that requires rapid intervention compared to other metastatic locations. This study measured and compared...

Cite
Fuller SN, Shafiei A, Venzon DJ, et al. Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Curr Oncol. 2021;28(6):4357-4366doi: 10.3390/curroncol28060370.
Fuller, S. N., Shafiei, A., Venzon, D. J., Liewehr, D. J., Mauda Havanuk, M., Ilanchezhian, M. G., Edgerly, M., Anderson, V. L., Levy, E. B., Hoang, C. D., Jones, E. C., Reilly, K. M., Widemann, B. C., Wood, B. J., Bagheri, H., & Del Rivero, J. (2021). Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Current oncology (Toronto, Ont.), 28(6), 4357-4366. https://doi.org/10.3390/curroncol28060370
Fuller, Sarah N, et al. "Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma." Current oncology (Toronto, Ont.) vol. 28,6 (2021): 4357-4366. doi: https://doi.org/10.3390/curroncol28060370
Fuller SN, Shafiei A, Venzon DJ, Liewehr DJ, Mauda Havanuk M, Ilanchezhian MG, Edgerly M, Anderson VL, Levy EB, Hoang CD, Jones EC, Reilly KM, Widemann BC, Wood BJ, Bagheri H, Del Rivero J. Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Curr Oncol. 2021 Nov 01;28(6):4357-4366. doi: 10.3390/curroncol28060370. PMID: 34898541; PMCID: PMC8628706.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 288 entries